Genmab A/S Price (GMAB.CO)

Stock Price

Low: Year Low
High: Year High

Market Cap

Fetching Data...

Enterprise Value

Fetching Data...

Fetching Data...

Shares Outstanding

64,632,940

(1.9446)%

Community Sentiment 0 votes
↑ 0% ↓ 0%

Description

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis... Read More

Sector: Healthcare

  • Previous Close Fetching Data...
  • Range $1315-2137
  • Market Cap 88.27B
  • Enterprise Value No Data
  • Avg Volume Fetching Data...
  • P/E Ratio Fetching Data...
  • Dividend Yield Fetching Data...

Industry: Biotechnology

  • ceo: Dr. Jan G.J. van de Winkel Ph.D.
  • IPO Date: October, 20, 2000
  • Country: DK
  • Currency: DKK
  • Headquaters: No Data
  • Employees: 2682

- Revenue from each product or segment:

Product or Segment Value: % - Total Last 3Y:
news-img

- Revenue by Region

Product or Segment Value: % - Total Last 3Y:
news-img
8 New Orders
close
Theme Customizer

Customize your theme

close

Theme variation